Literature DB >> 33035588

Nicotinamide and ascorbic acid nanoparticles against the hepatic insult induced in rats by high fat high fructose diet: A comparative study.

Hend Abd-Allah1, Maha Nasr2, Omar A H Ahmed-Farid3, Bassant M M Ibrahim4, Rofanda M Bakeer5, Rania F Ahmed4.   

Abstract

AIMS: Non-alcoholic fatty liver disease (NAFLD) caused by consumption of high levels of fat and sugars (HFHS) in diet is considered one of the most dangerous medical complications among children and adolescents. Nicotinamide is among the promising candidates in ameliorating HFHS diet-induced NAFLD, but its use is limited by the possibility of prompting hepatotoxicity in high doses. Ascorbic acid is another promising candidate, however its use as a hepatoprotective agent is limited by its chemical instability. Therefore, the aim of the study was to overcome their delivery limitations and enhance their hepatoprotective activity by loading into nanoparticles. KEY
FINDINGS: In the present study, upon incorporating nicotinamide or ascorbic acid in chitosan nanoparticles, they ameliorated the insulin-resistant status induced in rats by a high-fat-high-fructose (HFHF) diet. Both formulae decreased serum level of ALT and AST, as well as liver tissue total cholesterol, triglycerides and 8-hydroxy-2-deoxyguanosine (8-OHdG) levels. They also decreased oxidative and nitrosative stresses along with a significant increase in the hepatocellular energy. The biochemical findings were further confirmed by histopathological examination. Finally from the obtained data it could be concluded that chitosan nicotinamide nanoparticles at a dose level (10 mg/kg, p.o.) demonstrated beneficial pharmacological effect with safer toxicity profile than chitosan ascorbic acid nanoparticles. SIGNIFICANCE: Nicotinamide chitosan nanoparticles could be recommended as daily supplement in the recovery from NAFLD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ascorbic acid; Chitosan; Nanoparticles; Nicotinamide; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2020        PMID: 33035588     DOI: 10.1016/j.lfs.2020.118540

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  The Use of Chitosan-Coated Nanovesicles in Repairing Alcohol-Induced Damage of Liver Cells in Mice.

Authors:  Loredana Nicoleta Hilițanu; Liliana Mititelu-Tarțău; Maria Bogdan; Beatrice Rozalina Buca; Ana-Maria Raluca Păuna; Liliana Lăcrămioara Pavel; Ana-Maria Pelin; Andreea-Daniela Meca; Grațiela Eliza Popa
Journal:  Medicina (Kaunas)       Date:  2022-06-05       Impact factor: 2.948

2.  Biological and Pharmacological Characterization of Ascorbic Acid and Nicotinamide Chitosan Nanoparticles against Insulin-Resistance-Induced Cognitive Defects: A Comparative Study.

Authors:  Hend Abd-Allah; Maha Nasr; Omar A H Ahmed-Farid; Salma A El-Marasy; Rofanda M Bakeer; Rania F Ahmed
Journal:  ACS Omega       Date:  2021-01-25

3.  Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

Authors:  Rasha R El-Kady; Amani K Ali; Lamia M El Wakeel; Nagwa A Sabri; May A Shawki
Journal:  Ther Adv Chronic Dis       Date:  2022-02-23       Impact factor: 5.091

Review 4.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.